Skip to content
Biodatica
Start free

Akeso

Qilu, Shandong

Oncologygene editingPhase IIListed · 9926.HK

This company trades under its own ticker, so it sits outside Biodatica’s pre-ticker window. The record stays here because its filings are real, but the feed leaves listed companies out unless you ask for them.

Compare Sign in to watch

What changed

Phase II trial registered: Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

4w agoTrial registeredJun 15, 2026Source filing (opens the source filing in a new tab)

Momentum

73no change

Momentum 73 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase II

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    PHASE2 registered

    Jun 30, 2026

    Ovarian Cancer · NOT_YET_RECRUITING · sponsor: Shandong University · Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian Cancer

    ClinicalTrials.gov · NCT07647653 (opens the source filing in a new tab)

  2. Trial

    Study registered

    Dec 30, 2025

    Cervical Cancer Metastatic, Cervical Cancer Recurrent · NOT_YET_RECRUITING · sponsor: Qi Zhou · A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer

    ClinicalTrials.gov · NCT07266350 (opens the source filing in a new tab)

  3. Trial

    PHASE2 registered

    Apr 9, 2021

    Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm, Endometrial Neoplasms · COMPLETED · sponsor: Akeso · Study of AK112 in the Treatment of Advanced Gynecological Tumors

    ClinicalTrials.gov · NCT04870177 (opens the source filing in a new tab)

  4. Grant

    R01 · $592k · non-dilutive

    Mar 2, 2021

    PURDUE UNIVERSITY · PI ZHOU, QI · NHLBI · award ends Jan 31, 2028 · Aerosol delivery of combinational therapeutics targeting deadly lung infections

    NIH RePORTER · NIH RePORTER 11299489 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources